Oncology Business Management | Specialty

Best Practices in NSCLC Molecular Testing, Part I

February 13th 2013

Introduction: Advances and Issues in NSCLC

February 13th 2013

Squamous Cell Carcinoma Treatment Options

February 13th 2013

FDA Gives Radium-223 Priority Review Status

February 13th 2013

Radium Ra 223 Dichloride will be considered as a treatment for patients who have castration-resistant prostate cancer with bone metastases under the FDA's priority review program.

Ibrutinib Receives Breakthrough Designations for Mantle Cell Lymphoma and Waldenström's Macroglobulinemia

February 13th 2013

The investigational agent ibrutinib was granted "Breakthrough Therapy Designations" by the FDA as a singular therapy for a pair of B-cell malignancies: relapsed or refractory mantle cell lymphoma and Waldenström's macroglobulinemia.

Pomalidomide Approved for Relapsed or Refractory Multiple Myeloma

February 8th 2013

The FDA announced the approval of pomalidomide for the treatment of multiple myeloma after patients have relapsed or become refractory to other cancer drugs.

Advanced Prostate Cancer: Therapeutic Sequencing, Outcomes, and Cost Implications

February 7th 2013

There is a dramatic revolution under way in the treatment of advanced-stage prostate cancer, which for many years consisted of systemic chemotherapy that offered only palliation of symptoms and no hope of improved survival.

What Does Increased Payer Cost Management Mean for Oncology Practices?

February 6th 2013

Community practice viability may hinge on understanding and adapting to more aggressive payer involvement

Priority Review Granted to Afatinib for EGFR+ Advanced NSCLC

January 15th 2013

The FDA has accepted a NDA for afatinib to treat patients with locally advanced or metastatic NSCLC who have tested positive for an EGFR mutation that has been identified through a companion diagnostic test.

Oncology Enters the Informatics Era: Many Eager to Jump on the Health Information Highway

January 15th 2013

The unifying principle for care delivery in every situation should ideally be centered on complete clinical information, coupled with evidence-based medicine, and filtered through clinical decision support tools.

Unraveling the Layers: IDNs, ACOs, and the Future of Healthcare Integration

January 11th 2013

This recorded webinar features thought leader perspectives and key insights from HRA's newest research program - Understanding Integrated Delivery Networks.

CTCs Found to Be Predictive for Recurrence and Survival in Melanoma Patients

January 9th 2013

Circulating tumor cells can be a predictive blood biomarker for recurrence and survival in patients with stage III melanoma and may help identify who will benefit from aggressive adjuvant therapy.

Putting Practices on the RAC: Recovery Audit Contractors Scrutinize Oncology Practices

January 9th 2013

Since recovery audit contractors are paid a contingency fee for locating discrepancies, they are quickly becoming viewed as bounty hunters by many practices.

Novel Agents in Practice: Outcomes at What Cost?

January 5th 2013

The real question is how will we best use our continually evolving armamentarium of treatments to deliver the best outcomes while optimizing the cost of care for our patients.

"Fiscal Cliff" Deal Averts Severe Cuts to Medicare and Cancer Research

January 2nd 2013

After wrangling between Democrats and Republicans pushed a decision beyond a year-end deadline, the federal government passed the American Taxpayer Relief Act of 2012 and averted the "fiscal cliff."

Sequencing of Novel Prostate Cancer Agents Is a Work in Progress

December 26th 2012

Over the past decade, the availability of new agents with varying mechanisms of action has greatly enhanced the treatment landscape in castration-resistant prostate cancer.

The Challenges That Lie Ahead

December 13th 2012

As many of us are keenly aware, the coming 12 months present some very challenging times in the medical community.

Dr. Shore on Current Clinical Trial Challenges in CRPC

December 12th 2012

Effective Management of Prostate Cancer Conclusion

December 12th 2012

Revenue Opportunities and GPOs for Urology Groups

December 12th 2012